NCT00509249终止2 期
A Phase II Study of VEGF Trap (NSC 724770) in Patients With MDS
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Hematological Response Rate
研究概览
简要总结
This phase II trial is studying how well aflibercept works in treating patients with myelodysplastic syndromes. Aflibercept may be able to carry cancer-killing substances directly to myelodysplastic syndrome cells. It may also stop the growth of cancer cells by blocking blood flow to the cancer
详细描述
OBJECTIVES:
I. To determine the antitumor activity of aflibercept as assessed by the hematological response rate.
II. To determine overall and progression-free survival in patients with myelodysplastic syndromes.
III. To assess hematologic improvement and time to leukemic transformation. IV. To assess the toxicity profile of aflibercept in this patient population. V. To perform correlative studies to better understand the ability of aflibercept to reach and modulate its respective targets.
OUTLINE: This is a multicenter study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed myelodysplastic syndromes (MDS), including any of the following:
- •Secondary MDS
- •MDS/myeloproliferative disorders (MPD) (e.g., chronic myelomonocytic leukemia or atypical chronic myeloid leukemia)
- •IPSS scores of 0.5 or greater (≥ INT-1) OR transfusion dependent despite use of growth factors
- •No more than 20% blasts in the marrow
- •Patients who have not responded after 3 courses of hypomethylating agents (azacitidine or decitabine) OR; who are unable to tolerate hypomethylating agents OR who refused to receive hypomethylating agents are eligible for this study
- •ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
- •Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- •AST/ALT ≤ 2.5 x ULN
- •Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min
- •Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine collection
- •PT INR ≤ 1.5
- •Patients with PT INR > 1.5 on full-dose anticoagulants (e.g., warfarin) are eligible provided both of the following criteria are met:
- •Patient has an in-range INR (usually between 2 and 3) and is on a stable dose of oral anticoagulant or low molecular weight heparin
- •Patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- •Not pregnant or nursing
- •Fertile patients must use effective contraception during and for at least 6 months after completion of study treatment
- •Prior DNA-demethylating agent therapy or lenalidomide therapy allowed
- •Prior treatment with other molecular agents, such as thalidomide, valproic acid, or imatinib mesylate allowed
排除标准
- •Evidence of active malignancies other than squamous cell or basal cell carcinoma of the skin
- •Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study
- •Serious or non-healing wound, ulcer, or bone fracture
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- •Significant traumatic injury within the past 28 days
- •Clinically significant cardiovascular disease, including any of the following:
- •History of cerebrovascular accident (CVA) within the past 6 months
- •Uncontrolled hypertension, defined as blood pressure > 150/100 mm Hg or systolic BP > 180 mm Hg if diastolic blood pressure < 90 mm Hg (on at least 2 repeated determinations on separate days) within the past 3 months
- •Myocardial infarction or unstable angina within the past 6 months
- •New York Heart Association class III or IV congestive heart failure, serious cardiac arrhythmia requiring medication, or unstable angina pectoris within the past 6 months
- •Clinically significant peripheral vascular disease within the past 6 months
- •Pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within the past 6 months
- •Evidence of bleeding diathesis or coagulopathy
- •Concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements
- •Prior cytotoxic chemotherapy for MDS
- •Molecular therapy or immunosuppressive agents (including steroids) within the past 3 weeks
- •Other prior antiangiogenesis agents
- •Coronary artery bypass graft (CABG) within the past 6 months
- •Valproic acid should be discontinued at least 24 hours before aflibercept administration, unless needed for seizure control
- •Major surgical procedure or open biopsy within the past 28 days
- •Core biopsy (other than bone marrow biopsy) within the past 7 days
- •Anticipation of need for major surgical procedures during the course of the study
- •Patients may not be receiving any other investigational agents
结局指标
主要结局
Hematological Response Rate
时间窗: Up to 3 years
Complete Response (CR): repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.0x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia. Partial Response (PR): same as CR for peripheral blood except BM shows blasts decrease by ≥ 50% but still \> 5% or a less advanced FAB classification from pretreatment. Hematological response=CR+PR.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial CancerRecurrent Endometrial CarcinomaNCT00462826National Cancer Institute (NCI)49
已完成
2 期
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumAdenocarcinoma of the BladderDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerSquamous Cell Carcinoma of the BladderStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder CancerNCT00407485National Cancer Institute (NCI)22
已完成
1 期
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid TumorsUnspecified Childhood Solid Tumor, Protocol SpecificNCT00622414National Cancer Institute (NCI)27
已完成
2 期
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaFallopian Tube CancerFemale Reproductive CancerOvarian CarcinosarcomaOvarian SarcomaRecurrent Ovarian Epithelial CancerRecurrent Uterine SarcomaStage III Ovarian Epithelial CancerStage III Uterine SarcomaStage IV Ovarian Epithelial CancerStage IV Uterine SarcomaUterine CarcinosarcomaUterine LeiomyosarcomaNCT00390234National Cancer Institute (NCI)63
已完成
2 期
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerMetastatic Renal Cell CarcinomaNCT00357760National Cancer Institute (NCI)94